Press releases

Press releases

JDRF and Gubra join forces to develop a new glucose responsive insulin for diabetes

18 June, 2018 – JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such as type 1 diabetes (T1D). The Gubra approach is based on a novel, and unique concept that differs fundamentally from other glucose sensing insulin approaches and the JDRF funding commitment will help accelerate the program to its next development stage. Read more

Gubra strengthens board and top management

14 June, 2018 – Gubra has experienced a very positive development for a number of years and to keep evolving, Gubra has decided to expand the board and top management inducing additional business and technological competencies. Read more

Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments

7 September, 2017 – Today, Boehringer Ingelheim and Gubra announced a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. Read more

Gubra reaches third research milestone under a collaboration agreement with Sanofi

30 August, 2017 – Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity. Read more

Gubra appoints Chief Operating Officer

6 April, 2017 – As of 1 April 2017, Helle Kirstein Erichsen has been appointed COO of Gubra. In this newly created position Helle Kirstein Erichsen will focus on optimizing processes, logistics and resource utilization across the organization as well as ensure smooth daily operations. Read more


Gubra appoints new CSO

1 November, 2016 – Today, Gubra announced a change in its executive management team by appointing Keld Fosgerau as new CSO. With this change, Gubra is able to strengthen its CRO services and further advance the pipeline of internal research and drug discovery projects. Read more

Gubra and Clinical-Microbiomics Announces Pre-clinical Microbiome Partnership

29 August, 2016 – Gubra ApS and Clinical-Microbiomics A/S announced today a strategic partnership focusing on analyzing the role of the microbiome in conditions related to diabetes, obesity and NAFLD/NASH. diabetes, obesity and NAFLD/NASH. The combined expertise and resources of these two world-leading research companies will enable a fast and customer tailored pre-clinical assessment of the impact of drugs and diet on the gut microbiome. Read more

Gubra announces changes to executive management team

1 June, 2016 – Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has appointed CBO Henrik Blou as new CEO. In addition, Gubra has appointed Jan K. Villadsen as new CFO. Read more

Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity

23 September, 2013 – Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity. The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation. Read more


Hørsholm Kongevej 11B
2970 Hørsholm
+45 3152 ­2650